Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1815 in atopic dermatitis
NCT05121480Phase 2Completed
- Sponsor
- Evelo Biosciences
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Microbiome Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of EDP1815 in atopic dermatitis (AD) (4 cohorts), sponsored by Evelo Biosciences. Primary endpoint: Achievement of EASI-50 at 16 weeks. Started Jan 2022; status: completed.
02
Drugs
EDP1815
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05121480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121480.